Walmart Dropped 5% In The Last 6 Months: This Wall Street Firm Says 30% Gains Are Coming Soon
π Walmart shares dropped 5% over six months to trade around $119, underperforming peers Costco and Target despite a recent 10.52% monthly rebound.
π Global eCommerce grew 23% last quarter, now accounting for 24% of total net sales as the retailer pivots toward high-margin tech and media services.
π° Advertising revenue surged 38% and marketplace sales rose 52%, validating the strategic shift to alternative profit pools despite macro headwinds.
π Tigress Financial analyst Ivan Feinseth sets a $155 price target, projecting 30% upside based on high-margin ad revenue and supply chain automation.
βοΈ The consensus analyst target is $127.35 (7.2% upside), though the stock trades at a premium 38x forward earnings multiple that may limit near-term gains.
π‘οΈ Management plans to reinvest tariff refunds into lower prices, which could compress margins if operating income shrinks in the second half of the year.
π Pharmacy pricing legislation is expected to create a roughly 125 basis point drag on comparable sales growth for the remainder of the fiscal year.
π Walmart+ membership program achieved record net additions, indicating strong retention and growth among higher-income households.
π Of 43 analysts covering the stock, 37 hold Buy or Strong Buy ratings, though recent revisions have mostly trended downward following weak guidance.
- Global eCommerce grew 23% last quarter to comprise 24% of total net sales, signaling a successful strategic pivot toward high-margin digital services.
- Advertising revenue jumped 38% and marketplace sales rose 52%, validating the company's transformation into a tech and media business with alternative profit pools.
- Tigress Financial analyst Ivan Feinseth projects a 30% upside to $155, citing high-margin advertising revenue and supply chain automation as key growth drivers.
- The Walmart+ membership program posted record net additions, demonstrating strong engagement and growth among higher-income households.
- Full-year adjusted EPS guidance was raised to $2.80-$2.87, reflecting confidence in the company's ability to maintain profitability despite macro challenges.
- Shares dropped 5% over six months and fell from a peak of $135 after two brutal earnings reactions involving weak guidance and same-store sales misses.
- The stock trades at a premium 38x forward earnings multiple, which many analysts argue already prices in much of the anticipated growth from new business segments.
- Pharmacy pricing legislation is expected to create a roughly 125 basis point drag on comparable sales, potentially limiting top-line growth in the second half of the year.
- Recent analyst revisions have mostly gone down, with JPMorgan Chase cutting its price target from $137 to $125 despite maintaining an Overweight rating.